🚀 VC round data is live in beta, check it out!
LENZ Therapeutics Valuation Multiples
Discover revenue and EBITDA valuation multiples for LENZ Therapeutics and similar public comparables like Organogenesis, Senores Pharmaceuticals, Cellectis, Monopar Therapeutics and more.
LENZ Therapeutics Overview
About LENZ Therapeutics
LENZ Therapeutics Inc is a late-stage biopharmaceutical company focused on developing and commercializing therapies to improve vision and developing ophthalmic pharmaceutical products.. Its initial focus is the treatment of presbyopia, the inevitable loss of near vision that impacts the daily lives of nearly all people over 45.
Founded
2020
HQ
Employees
42
Website
Sectors
Financials (LTM)
EV
$176M
LENZ Therapeutics Financials
LENZ Therapeutics reported last 12-month revenue of $26M and negative EBITDA of ($79M).
In the same LTM period, LENZ Therapeutics generated $25M in gross profit, ($79M) in EBITDA losses, and had net loss of ($78M).
Revenue (LTM)
LENZ Therapeutics P&L
In the most recent fiscal year, LENZ Therapeutics reported revenue of — and EBITDA of ($59M).
LENZ Therapeutics expects next 12-month revenue of XXX and NTM EBITDA of XXX
| LTM | NTM | Last FY | FY 2026 | FY 2027 | FY 2028 | |
|---|---|---|---|---|---|---|
| Revenue | $26M | XXX | — | XXX | XXX | XXX |
| Gross Profit | $25M | XXX | — | XXX | XXX | XXX |
| Gross Margin | 96% | XXX | — | XXX | XXX | XXX |
| EBITDA | ($79M) | XXX | ($59M) | XXX | XXX | XXX |
| EBITDA Margin | (305%) | XXX | — | XXX | XXX | XXX |
| EBIT Margin | (329%) | XXX | — | XXX | XXX | XXX |
| Net Profit | ($78M) | XXX | ($50M) | XXX | XXX | XXX |
| Net Margin | (298%) | XXX | — | XXX | XXX | XXX |
Financial data powered by Morningstar, Inc.
LENZ Therapeutics Stock Performance
LENZ Therapeutics has current market cap of $377M, and enterprise value of $176M.
Market Cap Evolution
LENZ Therapeutics' stock price is $12.06.
| EV | Market Cap | Price 1D | Price 1M | Price 3M | Price 12M | EPS |
|---|---|---|---|---|---|---|
| $176M | $377M | 0.0% | XXX | XXX | XXX | $-1.59 |
Benchmark Trading Valuation Multiples by Industry
Sign up to access valuation multiples like growth-adjusted P/E, Rule of 40, next 12-month EV/Revenue, EBITDA multiples by industry, consensus analyst estimates and many more.
Start Free TrialLENZ Therapeutics Valuation Multiples
LENZ Therapeutics trades at 6.8x EV/Revenue multiple, and (2.2x) EV/EBITDA.
EV / Revenue (LTM)
LENZ Therapeutics Financial Valuation Multiples
As of March 21, 2026, LENZ Therapeutics has market cap of $377M and EV of $176M.
Equity research analysts estimate LENZ Therapeutics' 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX
LENZ Therapeutics has a P/E ratio of (4.9x).
| LTM | NTM | Last FY | FY 2026 | FY 2027 | FY 2028 | |
|---|---|---|---|---|---|---|
| Market cap (current) | $377M | XXX | $377M | XXX | XXX | XXX |
| EV (current) | $176M | XXX | $176M | XXX | XXX | XXX |
| EV/Revenue | 6.8x | XXX | — | XXX | XXX | XXX |
| EV/EBITDA | (2.2x) | XXX | (3.0x) | XXX | XXX | XXX |
| EV/EBIT | (2.1x) | XXX | (3.0x) | XXX | XXX | XXX |
| EV/Gross Profit | 7.1x | XXX | — | XXX | XXX | XXX |
| P/E | (4.9x) | XXX | (7.6x) | XXX | XXX | XXX |
| EV/FCF | — | XXX | (2.9x) | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Verified LENZ Therapeutics Valuation Multiples
Access all public comps and forward-looking valuation multiples like EV/Revenue in 2027, based on consensus analyst estimates. Powered by FactSet and Morningstar.
LENZ Therapeutics Margins & Growth Rates
LENZ Therapeutics' revenue in the last 12 month grew by 152%.
LENZ Therapeutics' revenue per employee in the last FY averaged $0.6M.
LENZ Therapeutics' rule of 40 is (153%) (metric relevant for SaaS companies only, counted as combined revenue growth rate and EBITDA margin).
LENZ Therapeutics' rule of X is 74% (created by Bessemer, rule of X is another metric to measure SaaS companies, ~1.5x stronger vs. the traditional Rule of 40, counted as revenue growth rate multiplied by 2.5 plus EBITDA margin).
LENZ Therapeutics Operational Valuation Multiples
| LTM | NTM | Last FY | FY 2026 | FY 2027 | FY 2028 | |
|---|---|---|---|---|---|---|
| Revenue Growth | 152% | XXX | — | XXX | XXX | XXX |
| EBITDA Margin | (305%) | XXX | — | XXX | XXX | XXX |
| EBITDA Growth | (10%) | XXX | 35% | XXX | XXX | XXX |
| Rule of 40 | — | XXX | (153%) | XXX | XXX | XXX |
| Bessemer Rule of X | — | XXX | 74% | XXX | XXX | XXX |
| Revenue per Employee | — | XXX | $0.6M | XXX | XXX | XXX |
| R&D Expenses to Revenue | 78% | XXX | — | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
LENZ Therapeutics Public Comps
See public comps and valuation multiples for other Biopharmaceuticals comps.
| EV/Revenue | EV/EBITDA | |||||
|---|---|---|---|---|---|---|
| LTM | 2026E | 2027E | LTM | 2026E | 2027E | |
| Organogenesis | XXX | XXX | XXX | XXX | XXX | XXX |
| Senores Pharmaceuticals | XXX | XXX | XXX | XXX | XXX | XXX |
| Cellectis | XXX | XXX | XXX | XXX | XXX | XXX |
| Monopar Therapeutics | XXX | XXX | XXX | XXX | XXX | XXX |
| Greenwich LifeSciences | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc.
LENZ Therapeutics M&A Activity
LENZ Therapeutics acquired XXX companies to date.
Last acquisition by LENZ Therapeutics was on XXXXXXXX, XXXXX. LENZ Therapeutics acquired XXXXXXXX for XXX (EV/Revenue multiple of XXX).
Latest Acquisitions by LENZ Therapeutics
| Acquired Company | Valuation | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
Get Verified M&A Valuation Multiples
Sign up to see revenue and EBITDA valuation multiples for 150K+ M&A deals.
Start Free TrialLENZ Therapeutics Investment Activity
LENZ Therapeutics invested in XXX companies to date.
LENZ Therapeutics made its latest investment on XXXXXXXX, XXXXX. LENZ Therapeutics invested in XXXXXXXX for XXX (EV/Revenue multiple of XXX).
Latest Investments by LENZ Therapeutics
| Company | Valuation | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
Benchmark 350K+ Funding Rounds and Disclosed VC Valuation Multiples
Sign up to see data on 350K+ funding rounds and disclosed revenue and EBITDA valuation multiples, from seed, through growth stage, to pre-IPO.
Start Free TrialAbout LENZ Therapeutics
| When was LENZ Therapeutics founded? | LENZ Therapeutics was founded in 2020. |
| Where is LENZ Therapeutics headquartered? | LENZ Therapeutics is headquartered in United States. |
| How many employees does LENZ Therapeutics have? | As of today, LENZ Therapeutics has over 42 employees. |
| Who is the CEO of LENZ Therapeutics? | LENZ Therapeutics' CEO is Evert B. Schimmelpennink. |
| Is LENZ Therapeutics publicly listed? | Yes, LENZ Therapeutics is a public company listed on Nasdaq. |
| What is the stock symbol of LENZ Therapeutics? | LENZ Therapeutics trades under LENZ ticker. |
| When did LENZ Therapeutics go public? | LENZ Therapeutics went public in 2024. |
| Who are competitors of LENZ Therapeutics? | LENZ Therapeutics main competitors are Organogenesis, Senores Pharmaceuticals, Cellectis, Monopar Therapeutics. |
| What is the current market cap of LENZ Therapeutics? | LENZ Therapeutics' current market cap is $377M. |
| What is the current revenue of LENZ Therapeutics? | LENZ Therapeutics' last 12 months revenue is $26M. |
| What is the current revenue growth of LENZ Therapeutics? | LENZ Therapeutics revenue growth (NTM/LTM) is 152%. |
| What is the current EV/Revenue multiple of LENZ Therapeutics? | Current revenue multiple of LENZ Therapeutics is 6.8x. |
| Is LENZ Therapeutics profitable? | No, LENZ Therapeutics is not profitable. |
| What is the current EBITDA of LENZ Therapeutics? | LENZ Therapeutics has negative EBITDA and is not profitable. |
| What is LENZ Therapeutics' EBITDA margin? | LENZ Therapeutics' last 12 months EBITDA margin is (305%). |
| What is the current EV/EBITDA multiple of LENZ Therapeutics? | Current EBITDA multiple of LENZ Therapeutics is (2.2x). |
Start Your
Free Trial Today
Try Multiples for free for 3 days. Got questions or need a demo? Schedule a call with us below.